Radiation safety study aims to personalize thyroid cancer treatment

NCT ID NCT03986437

Completed Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study collects standard-of-care images from people with differentiated thyroid cancer who are treated with radioactive iodine (Iodine-131). The goal is to better understand how much radiation reaches healthy organs and what dose is needed to destroy thyroid tissue. By gathering this data, researchers hope to develop safer, more personalized treatment plans and support future large-scale studies on the effects of low-dose radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iodine-131
What this could lead to: If successful, this could help doctors personalize Iodine-131 doses to reduce radiation exposure to healthy organs while still effectively treating thyroid cancer.
What could go wrong: This is an observational study that only collects images, not a treatment trial. It may not directly lead to changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFERENTIATED THYROID CANCER

Contacts and locations

Locations

IUCT-O

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.